10 research outputs found
Supplementary Figure S1 from Immune Marker Spatial Distribution and Clinical Outcome after PD-1 Blockade in Mismatch Repair–deficient, Advanced Colorectal Carcinomas
Supplementary Figure S1. PD-L1 (green) was expressed in (A) CD3+ T lymphocytes (magenta/pink), (B) CD68+ macrophages (red), panCK+ (cyan/light blue) tumor cells, and (C) tumor cells (red). PD-1 expression on CD8+ T lymphocytes was also observed.</p
Supplementary Table S1 from Immune Marker Spatial Distribution and Clinical Outcome after PD-1 Blockade in Mismatch Repair–deficient, Advanced Colorectal Carcinomas
Supplementary Table S1. Significant features in the univariable analysis for prediction of progression-free survival.</p
Supplementary Table S2 from Immune Marker Spatial Distribution and Clinical Outcome after PD-1 Blockade in Mismatch Repair–deficient, Advanced Colorectal Carcinomas
Supplementary Table S2. Significant features in the univariable analysis for prediction of tumor response.</p
Supplementary Table S3 from Associations between AI-Assisted Tumor Amphiregulin and Epiregulin IHC and Outcomes from Anti-EGFR Therapy in the Routine Management of Metastatic Colorectal Cancer
Representativeness of study participants</p
Supplementary Figure S3 from Associations between AI-Assisted Tumor Amphiregulin and Epiregulin IHC and Outcomes from Anti-EGFR Therapy in the Routine Management of Metastatic Colorectal Cancer
Scatterplot: AREG vs EREG</p
Supplementary Methods S1 from Associations between AI-Assisted Tumor Amphiregulin and Epiregulin IHC and Outcomes from Anti-EGFR Therapy in the Routine Management of Metastatic Colorectal Cancer
Supplementary methods</p
Supplementary Table S2 from Associations between AI-Assisted Tumor Amphiregulin and Epiregulin IHC and Outcomes from Anti-EGFR Therapy in the Routine Management of Metastatic Colorectal Cancer
AREG/EREG with variation in tissue processing</p